EUVIMEDEUVIMED entdecken
Crossref

MPXV infection impairs IFN response but is partially sensitive to IFN-γ antiviral effect

Licia Bordi, Alessandra D'Auria, Federica Frasca, Valentina Mazzotta, Paola Mazzetti, Matteo Fracella, Gabriella d'Ettorre, Guido Antonelli, Mauro Pistello, Andrea Antinori, Raphael P Viscidi, Fabrizio Maggi und 2 weitere

Medical Microbiology and Immunology · 2024

DOI: 10.1007/s00430-024-00808-w ↗

Kurz gefasst

Fachartikel in der Zeitschrift Medical Microbiology and Immunology, 2024. Verfasst von Licia Bordi und 13 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Virology, National Institute for Infectious Diseases "Lazzaro Spallanzani" IRCCS, Rome, Italy. Hauptthemen laut MEDLINE: Interferon-gamma, Monkeypox virus. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 45 Literaturangaben. Gefördert von: Next Generation EU-MUR PNRR Extended Partnership initiative on Emerging Infectious Diseases (Project n. PE00000007, INF-ACT), Programma Ricerca Corrente—Linea 1 on emerging and re-emerging infections, Italian Ministry of Health, Progetti Ateneo 2022 Sapienza University of Rome, Italy.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The recent outbreak of monkeypox virus (MPXV) has caused global concern. How the virus evades the interferon (IFN) response is still poorly understood. We analyzed type I/II IFN (IFN-I/II) expression in clinical samples from MPXV-infected patients and measured IFN-I kinetics in MPXV-infected cells. We also evaluated the anti-MPXV activity of IFN-I/II in A549, HeLa and Vero-E6 cell lines. IFN-I/II mRNA expression was detected in skin lesions, anal swabs, nasopharyngeal samples and peripheral blood mononuclear cells (PBMC), with the highest levels in skin lesions (p < 0.05). High MPXV DNA levels in clinical samples were associated with increased IFN-I levels. In vitro, MPXV infection induced a peak of IFN-I between 48 and 72 h post-infection (p < 0.01). Pre-treatment of the A549, HeLa and Vero-E6 cells with high concentrations (≥ 100,000 International Unit, IU/ml) of IFN-α and IFN-ω did not inhibit or had little effect on MPXV replication, while IFN-β moderately reduced MPXV replication by 2.7-1.5 log10 at 100,000 IU/ml. In clinical samples there was a trend for elevated levels of IFN-γ in association with lower MPXV load and in vitro IFN-γ (3,600 IU/ml) strongly reduced viral titers by 3.4-1.6 log10. There were no significant differences in expression of select IFN-stimulated genes (ISGs) in MPXV infection in vitro. This study shows that MPXV delays IFN-I induction and inhibits expression of selected ISGs in vitro and is associated with an IFN-I resistance phenotype in vivo. However, MPXV is less resistant to IFN-γ in vivo and is sensitive to IFN-γ treatment in vitro, suggesting a potential therapeutic role for IFN-γ.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Interferon-gammaMonkeypox virusHumansAnimalsChlorocebus aethiopsVero CellsVirus ReplicationAntiviral AgentsHeLa CellsLeukocytes, MononuclearInterferonsMpox, Monkeypox

Stichwörter der Autor:innen

IDOIFN-γISGInnate immunityMonkeypox virusType I IFN

Substanzen

Interferon-gammaAntiviral AgentsInterferons

Autor:innen und Institutionen

  • Laboratory of Virology, National Institute for Infectious Diseases "Lazzaro Spallanzani" IRCCS, Rome, Italy.
  • Department of Molecular Medicine, Laboratory of Virology, Sapienza University of Rome, Rome, Italy.
  • Department of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, Italy.
  • Clinical Department, National Institute for Infectious Diseases "Lazzaro Spallanzani" IRCCS, Rome, Italy.
  • Department of Translational Research, Virology Section and Retrovirus Centre, University of Pisa, Pisa, Italy.
  • Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, MD, USA.

Förderung

  • Next Generation EU-MUR PNRR Extended Partnership initiative on Emerging Infectious Diseases (Project n. PE00000007, INF-ACT)
  • Programma Ricerca Corrente—Linea 1 on emerging and re-emerging infections, Italian Ministry of Health
  • Progetti Ateneo 2022 Sapienza University of Rome, Italy

Zitieren

APA

Bordi, L., D'Auria, A., Frasca, F., Mazzotta, V., Mazzetti, P., Fracella, M., d'Ettorre, G., Antonelli, G., Pistello, M., Antinori, A., Viscidi, R. P., Maggi, F., Lalle, E., & Scagnolari, C. (2024). MPXV infection impairs IFN response but is partially sensitive to IFN-γ antiviral effect. Medical Microbiology and Immunology. https://doi.org/10.1007/s00430-024-00808-w

Vancouver

Bordi L, D'Auria A, Frasca F, Mazzotta V, Mazzetti P, Fracella M, et al. MPXV infection impairs IFN response but is partially sensitive to IFN-γ antiviral effect. Medical Microbiology and Immunology. 2024. doi:10.1007/s00430-024-00808-w

BibTeX
@article{Bordi2024,
  author = {Bordi, Licia and D'Auria, Alessandra and Frasca, Federica and Mazzotta, Valentina and Mazzetti, Paola and Fracella, Matteo and d'Ettorre, Gabriella and Antonelli, Guido and Pistello, Mauro and Antinori, Andrea and Viscidi, Raphael P and Maggi, Fabrizio and Lalle, Eleonora and Scagnolari, Carolina},
  title = {MPXV infection impairs IFN response but is partially sensitive to IFN-γ antiviral effect},
  journal = {Medical Microbiology and Immunology},
  year = {2024},
  doi = {10.1007/s00430-024-00808-w}
}
Kostenlos starten →